Our vertical integration with Nanjing King-Friend Biochemical Pharmaceutical Co. (NKF) and the ongoing investment in manufacturing infrastructure enhance our overall capacity to support a robust and growing pipeline. With multiple FDA [US Food and Drug Administration]-approved manufacturing lines and plans for further expansion, we are well-positioned to meet increasing demand and regulatory requirements.

Additionally, our ability to collaborate with biopharmaceutical partners – by acting as a license holder in the US when partnering with CMOs – further strengthens our strategic flexibility.

Our expanded teams in regulatory, quality, and commercial functions enable us to effectively navigate market opportunities now and in the future.

Pipeline And Parent: Meitheal CEO Shea Talks Paclitaxel And What’s Next

Exclusive Interview Includes Discussion Of Vision To Grow In US Biosimilars

More from Interviews

More from Biosimilars